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Aims
To investigate the efficacy, toxicity and cosmetic results of
partial breast irradiation (PBI) administered with high-
dose-rate brachytherapy (BRT-HDR) in elderly patients
(≥65 years) with stage I–II breast cancer.
Materials and methods
Between August 2003 and July 2008, 50 women (median
age 65 years; range 65–84; 45 with infiltrating ductal, 1
infiltrating tubular, 1 infiltrating papillary and 3 DCIS)
were enrolled in a phase II prospective study. Treatment
schedule was 4 Gy twice a day for a total dose of 32 Gy,
with a minimum interval of 6 hours between the two daily
fraction Therapy was delivered using a microSelectron
HDR 192Ir remote afterloading system (Nucletron, The
Netherlands). Catheter implantation was performed dur-
ing surgery or re-excision (in patients with positive or
"close" margins) in 7 cases and postoperatively, at a
median of 8 weeks (range 4–12) after surgery, in 43
patients. Two patients received adjuvant chemotherapy:
CMF for 6 cycles in 1, and epirubicine for 14 weekly
administrations in the other one. Adjuvant hormone ther-
apy was prescribed for 39 patients (tamoxifen in 25 and
anastrozole in 14).
Results
At a median follow-up of 32 months (range 5–63), acute
G1 skin toxicity occurred in 2 cases; late subcutaneous tox-
icity in 3 (2 G1 and 1 G2); teleangiectasia occurred in 7
patients while fat necrosis occurred in 3 cases. Cosmetic
results (evaluated by radiation oncologists and patients)
were good to excellent in all cases.
At the last check-up all patients were alive except one, who
died of haepatic adenocarcinoma; one patient developed
contra-lateral breast cancer, one patient developed kidney
oncocitoma, one patient NSCLC and another one squa-
mous cell carcinoma of the vulva.
One patient, 4 years after PBI, developed a tumour in the
same breast, but in another quadrant, (pT2a N2aM0, infil-
trating ductal G2 ER 40%, PgR 40%, Ki-67 10%, cERb-B2
1+) and was successfully treated with mastectomy and
lymph node dissection followed by external beam radio-
therapy (chest wall and supraclavicular fossa); one patient
developed axillary nodal recurrence and was treated with
radiotherapy alone (axillary nodes).
Conclusion
In conclusion, PBI with interstitial HDR brachytherapy is
a valid option in the management of selected aged
patients with early breast cancer. The technique is feasible,
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reproducible and associated with very low perioperative
and acute toxicity. A longer follow-up in our series will be
useful to evaluate the incidence of late toxicity and local
relapse.Page 2 of 2
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